Thermo Fisher Scientific Inc. And Precision Health Research, Singapore (PRECISE) Team Up To Advance PRECISE-SG100K, One Of Asia’s Largest Population-Scale Proteomics Studies

Thermo Fisher Scientific Inc., a global leader in serving science, announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to support the PRECISE-SG100K study. This initiative is one of the most significant and diverse population-scale biobank programs in the region and reflects a growing global trend toward using proteomics to understand real-time disease biology, improve early detection and enable more personalized approaches to medicine.

As national biobanks become central to public health strategies worldwide, the integration of multi-omic platforms with advanced AI analytics is becoming essential. High-quality proteomic and clinical datasets analyzed with AI can reveal complex biological patterns that improve patient stratification and accelerate the translation of scientific discoveries into practical, clinical insights.

Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific, emphasized that population-scale proteomics presents one of the greatest opportunities to understand disease across the entire spectrum of human health. He added that by combining the company’s scientific expertise with advanced technologies, Thermo Fisher is helping national health systems generate insights that have the potential to transform disease prevention and patient care.

Under the PRECISE-SG100K program, Thermo Fisher will implement a comprehensive proteomics strategy that integrates the Olink® Proximity Extension Assay (PEA) platforms with its high-resolution Orbitrap Astral mass spectrometry system. Used together with the Proteograph® Product Suite from Seer, Inc., this combination provides scalable and highly sensitive protein measurement alongside deep, unbiased discovery proteomics. The result is a powerful framework capable of converting large volumes of biological data into meaningful insights on disease mechanisms and new biomarker opportunities.

The study’s design uses these complementary technologies in parallel across a large and diverse longitudinal cohort. This approach enhances reproducibility, supports regulatory-grade evidence generation and increases the long-term translational value of the biobank. It reflects the broader shift in which proteomics is becoming not just a discovery tool, but a foundational component of precision medicine infrastructure.

Karen Nelson, Ph.D., chief scientific officer at Thermo Fisher, noted that national-scale initiatives require technologies that can deliver both broad coverage and highly precise measurements. By combining Thermo Fisher’s leading platforms, the collaboration aims to accelerate accurate biomarker discovery and improve the speed at which new scientific insights can be translated into clinical applications.

By comparing data generated through Thermo Fisher’s platforms with expanding public proteomic datasets from major global population studies, researchers will gain significant capacity for discovery, validation and accelerated translation. Thermo Fisher’s experience in supporting large biobank and population genetics programs worldwide reinforces this capability. The company currently participates in major initiatives such as the UK Biobank Pharma Proteomics Project, FinnGen, and the MyCode Community Health Initiative, collectively involving more than one million samples.

John Chambers, Ph.D., chief scientific officer of PRECISE and principal investigator of the PRECISE-SG100K study, highlighted that applying this integrated proteomics approach across Singapore’s diverse population provides a dynamic view of disease biology. He noted that this model strengthens the ability to detect early molecular indicators of disease, understand risk across global communities and generate insights that can shape the future of population-level health strategies.

The PRECISE-SG100K study is supported by Novogene, which provides laboratory services for sample processing and data generation, alongside research collaboration partner Seer, Inc.

Also Read

Thermo Fisher Launches CTS Compleo Automated System To Transform Cell Therapy Fill-Finish Manufacturing